Business
Viridian Therapeutics Announces Positive Topline Results from Elegrobart Phase 3 REVEAL?1 Clinical Trial in Active Thyroid Eye Disease
- REVEAL-1 met the primary endpoint of Q4W proptosis responder rate (PRR) with a highly statistic...
About this update from Viridian Metals Inc
[{"type":"text","content":"Viridian Therapeutics Announces Positive Topline Results from Elegrobart Phase 3 REVEAL‑1 Clinical Trial in Active Thyroid Eye Disease\n\n\n .bwalignc { text-align: center; list-style-position: inside }\n.bwblockalignl { margin-left: 0px; margin-right: auto }\n.bwcellpmargin { margin-bottom: 0px; margin-top: 0px }\n.bwleftsingle { border-left: solid black 1pt }\n.bwlistdisc { list-style-type: disc }\n.bwpadb3 { padding-bottom: 4px }\n.bwpadl0 { padding-left: 0px }\n.bwpadl2 { padding-left: 10px }\n.bwpadr0 { padding-right: 0px }\n.bwrightsingle { border-right: solid black 1pt }\n.bwsinglebottom { border-bottom: solid black 1pt }\n.bwtablemarginb { margin-bottom: 10px }\n.bwuline { text-decoration: underline }\n.bwvertalignb { vertical-align: bottom }\n.bwvertalignm { vertical-align: middle }\n.bwwidth10 { width: 10% }\n.bwwidth100 { width: 100% }\n.bwwidth15 { width: 15% }\n.bwwidth37 { width: 37% }\n.bwwidth8 { width: 8% }\n \n\n\n\n\n - REVEAL-1 met the primary endpoint of Q4W proptosis responder rate (PRR) with a highly statistically significant treatment effect -\n \n\n\n\n - Elegrobart Q4W and Q8W achieved clinically meaningful 54% and 63% PRR versus 18% placebo at week 24 -\n \n\n\n\n - Complete resolution of diplopia in 51% of patients treated Q4W versus 16% placebo at week 24 -\n \n\n\n\n - Elegrobart was generally well tolerated in both dose groups with low rates of hearing impairment -\n \n\n\n\n - REVEAL-2, a phase 3 clinical trial evaluating elegrobart in patients with chronic TED, is on track for topline readout in Q2 2026; BLA submission anticipated in Q1 2027 -\n \n\n\n\n - Viridian ended Q4 2025 with $875 million in cash; the company anticipates existing cash, potential near-term milestones from its 2025 royalty agreement, and anticipated commercial revenues from veligrotug and elegrobart if approved, to fund current business plans through profitability -\n \n\n\n\n - Conference call and webcast to be held today, March 30th at 8:00 a.m. ET -\n \n\n\n\n\n Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for serious and rare diseases, today announced positive topline data from the elegrobart REVEAL-1 phase 3 clinical trial in patients with active thyroid eye disease (TED). Elegrobart is a subcutaneo...